Tcelltech Inc.
Clinical trials sponsored by Tcelltech Inc., explained in plain language.
-
Engineered immune cells take on Hard-to-Treat sarcomas in first human test
Disease control Recruiting nowThis early-stage trial is testing a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcomas that have stopped responding to standard treatments. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells. The…
Phase: PHASE1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take on deadliest brain cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment called TX103 CAR-T cells for people with recurrent or progressive grade 4 glioma, a very aggressive brain cancer. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells, and in…
Phase: PHASE1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals …
Phase: PHASE1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC